Surgery Partners, Inc. (NASDAQ:SGRY) Receives $36.56 Average PT from Analysts

Surgery Partners, Inc. (NASDAQ:SGRY) has received a consensus rating of “Moderate Buy” from the ten brokerages that are currently covering the firm, MarketBeat.com reports. Three analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $36.56.

Several equities analysts have commented on SGRY shares. JPMorgan Chase & Co. dropped their price target on shares of Surgery Partners from $38.00 to $28.00 and set a “neutral” rating for the company in a research note on Tuesday, December 3rd. KeyCorp started coverage on shares of Surgery Partners in a research report on Friday, October 11th. They set a “sector weight” rating for the company. UBS Group initiated coverage on shares of Surgery Partners in a research report on Monday, October 14th. They set a “buy” rating and a $38.00 price objective for the company. Macquarie reissued an “outperform” rating and issued a $34.00 price target on shares of Surgery Partners in a research report on Tuesday, November 19th. Finally, Bank of America started coverage on shares of Surgery Partners in a research note on Monday, December 16th. They issued a “buy” rating and a $30.00 price objective on the stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. KBC Group NV grew its position in Surgery Partners by 31.8% during the third quarter. KBC Group NV now owns 2,385 shares of the company’s stock worth $77,000 after buying an additional 576 shares during the period. Point72 Asia Singapore Pte. Ltd. lifted its holdings in shares of Surgery Partners by 747.6% in the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,831 shares of the company’s stock valued at $124,000 after purchasing an additional 3,379 shares in the last quarter. Creative Planning purchased a new stake in shares of Surgery Partners in the third quarter valued at about $258,000. Versor Investments LP purchased a new stake in shares of Surgery Partners in the third quarter valued at about $271,000. Finally, MeadowBrook Investment Advisors LLC lifted its holdings in shares of Surgery Partners by 16.6% in the fourth quarter. MeadowBrook Investment Advisors LLC now owns 10,280 shares of the company’s stock valued at $218,000 after purchasing an additional 1,460 shares in the last quarter.

Surgery Partners Stock Down 0.5 %

Shares of NASDAQ SGRY opened at $25.65 on Friday. The company has a 50 day simple moving average of $21.76 and a 200-day simple moving average of $26.99. The company has a market capitalization of $3.26 billion, a P/E ratio of -53.44, a P/E/G ratio of 17.66 and a beta of 2.60. The company has a debt-to-equity ratio of 0.99, a current ratio of 1.80 and a quick ratio of 1.66. Surgery Partners has a 1 year low of $19.50 and a 1 year high of $35.29.

Surgery Partners (NASDAQ:SGRY) last posted its earnings results on Tuesday, November 12th. The company reported $0.19 earnings per share for the quarter, missing the consensus estimate of $0.25 by ($0.06). The company had revenue of $770.40 million during the quarter, compared to analyst estimates of $768.99 million. Surgery Partners had a negative net margin of 2.03% and a positive return on equity of 2.85%. The firm’s revenue for the quarter was up 14.3% on a year-over-year basis. During the same quarter last year, the business posted $0.15 EPS. On average, equities research analysts predict that Surgery Partners will post 0.71 earnings per share for the current year.

About Surgery Partners

Surgery Partners, Inc, together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery.